Key Developments: Galena Biopharma Inc (GALE.PH)

GALE.PH on Philadelphia Stock Exchange

1.79USD
12:35pm EDT
Change (% chg)

$0.09 (+5.29%)
Prev Close
$1.70
Open
$1.72
Day's High
$1.79
Day's Low
$1.69
Volume
20,975
Avg. Vol
9,761
52-wk High
$3.56
52-wk Low
$1.28

Search Stocks

Latest Key Developments (Source: Significant Developments)

Galena Biopharma Inc reiterates FY 2015 revenue guidance
Thursday, 7 May 2015 04:15pm EDT 

Galena Biopharma Inc:Says FY 2015 net revenue guidance reiterated at $15 million -$18 million.FY 2015 revenue of $16 million - Thomson Reuters I/B/E/S.  Full Article

Galena Biopharma announces closing of public offering of common stock and warrants
Wednesday, 18 Mar 2015 04:35pm EDT 

Galena Biopharma:Closes underwritten public offering of 24,358,974 shares of common stock, and warrants to purchase an aggregate of 12,179,487 shares of common stock at an exercise price of $2.08 per share.Underwriters also exercised their over-allotment option to purchase warrants to purchase an aggregate of 1,826,923 shares of common stock.Warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance.Shares of common stock and warrants are immediately separable and will be issued separately.Net proceeds to Galena are expected to be about $35.4 mln, assuming no exercise of the warrants and after deducting underwriting discounts and commissions and estimated offering expenses payable by Galena.Raymond James & Associates, Inc. acted as the sole book-running manager for the offering.Roth Capital Partners acted as lead manager, and Maxim Group LLC, Noble Life Science Partners, and MLV & Co. LLC acted as co-managers.Intends to use the net proceeds from this offering to fund its operations, including the ongoing commercialization of Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film, its ongoing Phase 3 PRESENT study and other clinical trials of its product candidates.Also uses for other working capital and general corporate purposes.  Full Article

Galena Biopharma announces pricing of public offering of common stock and warrants
Friday, 13 Mar 2015 09:23am EDT 

Galena Biopharma Inc:Pricing of an underwritten public offering of 24,358,974 units at a public offering price of $1.56 per unit, for total gross proceeds of $38.0 million.Each unit consists of one share of common stock and a warrant to purchase 0.5 of a share of common stock at an exercise price of $2.08 per share.The warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance.The shares of common stock and warrants are immediately separable and will be issued separately.The offering is expected to close on March 18.Raymond James & Associates, Inc. is acting as the sole book-running manager for the offering. Roth Capital Partners is acting as lead manager, and Maxim Group LLC, MLV & Co. LLC, and Noble Life Science Partners are acting as co-managers.Company intends to use net proceeds from this offering to fund operations.Including ongoing commercialization of Abstral Sublingual Tablets and Zuplenz Oral Soluble Film, ongoing Phase 3 PRESENT study and other clinical trials of its product candidates, and for other working capital and general corporate purposes.  Full Article

Galena Biopharma announces proposed public offering of common stock and warrants
Thursday, 12 Mar 2015 04:01pm EDT 

Galena Biopharma Inc:Intends to offer shares of its common stock and warrants to purchase its common stock in an underwritten public offering.The shares of common stock and warrants to purchase common stock are being offered as units.The shares of common stock and warrants are immediately separable and will be issued separately.Says Raymond James will act as sole book-running manager for the offering.Company intends to use net proceeds from this offering to fund operations.Including ongoing commercialization of Abstral Sublingual Tablets and Zuplenz Oral Soluble Film, ongoing Phase 3 PRESENT study and other clinical trials of product candidates, and for other working capital and general corporate purposes.  Full Article

Galena Biopharma Inc reiterates FY 2015 revenue guidance
Thursday, 5 Mar 2015 04:10pm EST 

Galena Biopharma Inc:Reiterates FY 2015 net revenue guidance between $15-$18 million for the combined commercial programs.FY 2015 revenue of $18 million - Thomson Reuters I/B/E/S.  Full Article

Galena Biopharma Inc reaffirms FY 2014 revenue outlook
Thursday, 8 Jan 2015 07:00am EST 

Galena Biopharma Inc:Reiterates FY 2014 net revenues guidance to fall in the middle of $8-$10 mln range.FY 2014 revenue of $8.7 mln - Thomson Reuters I/B/E/S.  Full Article

Galena Biopharma Inc announces purchase agreement for up to $55.0 mln with Lincoln Park Capital Fund, LLC
Thursday, 20 Nov 2014 04:20pm EST 

Galena Biopharma Inc:Announces execution of a purchase agreement for up to $55.0 million with Lincoln Park Capital Fund, LLC (LPC).Under the terms of the purchase agreement dated Nov. 18, 2014, LPC initially purchased $5.0 million of Galena common stock at a price of $2.00 per share.Thereafter, at its sole discretion, Galena may sell up to $50 million worth of common stock to LPC over the 36 month term of the purchase agreement.Plans to use the proceeds received for its commercial and product development activities and for other working capital and general corporate purposes.  Full Article

Galena Biopharma Inc presents GALE-301 (Folate Binding Protein Immunotherapy) phase 2a clinical trial data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting
Friday, 7 Nov 2014 07:05am EST 

Galena Biopharma Inc:Announced data from its Phase 1/2a trial of GALE-301, a Folate Binding Protein (FBP)-derived immunotherapy, will be presented on Nov. 07 at the upcoming Society for Immunotherapy of Cancer (SITC) 29(th)Annual Meeting.GALE-301 is a peptide immunotherapy given as an adjuvant treatment to prevent recurrences in high-risk, ovarian and endometrial cancer patients rendered disease-free after completing standard of care therapy.Says the Phase 2a is an open-label trial with two arms consisting of HLA-A2 positive patients treated with the FBP peptide in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) and HLA-A2 negative patients followed prospectively as an untreated control group.Says the primary objectives of the trial are to measure the immune response, time to recurrence and overall survival between treatment arms. The preliminary results indicate GALE-301 is well tolerated and elicits a strong in vivo immune response.Says the study was not powered for efficacy but rather, a clinical proof of concept study.Says GALE-301 generates a long lasting immune response, which generates tumor lysing CD8 T cells, bypassing the need for active receptor or ligand binding to generate efficacy.  Full Article

Galena Biopharma Inc reaffirms FY 2014 revenue guidance - Conference Call
Monday, 3 Nov 2014 05:00pm EST 

Galena Biopharma Inc:Says it remain confident in achieving FY 2014 net revenue guidance of $8 million to $10 million.FY 2014 revenue of $10 million - Thomson Reuters I/B/E/S.  Full Article

Galena Biopharma Inc lowers FY 2014 revenue guidance - Conference Call
Thursday, 25 Sep 2014 05:00pm EDT 

Galena Biopharma Inc:Adjusts guidance for FY 2014 net revenues to $8 million to $10 million.FY 2014 revenue of $12 million - Thomson Reuters I/B/E/S.  Full Article

Search Stocks